# Three Very Different Research Stories

> Compare GHK-Cu, GLOW, and Melanotan II — Age Defying Peptides — A side-by-side comparison of three Skin & Aesthetics research peptides — GHK-Cu, the GLOW blend, and Melanotan II — across mechanism, evidence maturity, and safety profile.

**SKIN & AESTHETICS RESEARCH / MATRIX**

How a naturally occurring copper peptide, an untested supplier blend, and a synthetic pigment-signaling analog compare on mechanism, evidence, and risk.

## The short version

This page lines up [GHK-Cu](/ghk-cu), [GLOW](/glow), and [Melanotan II](/melanotan-2) on the dimensions that matter most when reading this research honestly: what mechanism each targets, how mature the evidence actually is, and what the safety literature actually shows. The headline is not subtle. GHK-Cu has the longest cosmetic-safety record and the most controlled human data of the three. GLOW borrows GHK-Cu's evidence for one of its three ingredients but has never itself been tested as a combined product. Melanotan II has the most serious documented case-report safety findings of anything on this site, including melanoma and kidney injury. None of this is medical advice, and no page on this site recommends a human dose.

## The comparison matrix

| Dimension | GHK-Cu | GLOW (research blend) | Melanotan II |
| --- | --- | --- | --- |
| What it targets | Collagen, elastin, and matrix repair via copper delivery and gene-expression effects | Matrix repair (GHK-Cu) plus vascular/cytoprotective (BPC-157) plus cell-migration (TB-500) signals | Skin pigmentation and appetite/sexual signaling via melanocortin receptors |
| Naturally occurring? | Yes — the GHK sequence occurs in human collagen and circulates in plasma | Partly — one of three ingredients (GHK-Cu) is natural; the other two are synthetic | No — a fully synthetic analog of a natural hormone |
| Evidence base | Small controlled human trials (incl. a placebo-controlled hair trial), decades of cell and topical research [1][3][4] | No trial of the combination; extrapolated entirely from single-ingredient literature [8][9][10] | Small Phase 1-scale human trials plus an extensive published case-report literature [11][13][15] |
| Route studied | Primarily topical (cosmetic); injectable/systemic use is unapproved and far less studied | Injectable, following its individual ingredients' research routes | Subcutaneous injection in both trials and community use |

## Mechanism

GHK-Cu works by delivering copper to tissue, enabling the collagen- and elastin-cross-linking enzyme lysyl oxidase, and by acting as a broad gene-expression signal that tilts cells toward repair and away from inflammation [2]. GLOW layers two additional mechanisms on top of GHK-Cu's: BPC-157's pro-angiogenic, VEGFR2-driven vascular protection [10], and TB-500's actin-binding, cell-migration effects — three distinct mechanisms bundled into one product, never tested together. Melanotan II works through an entirely different system: non-selective activation of melanocortin receptors, which raises pigment production through MC1R and separately affects appetite and sexual response through MC3R/MC4R in the brain. The three compounds do not compete for the same biological territory — they sit in genuinely different parts of the skin-aging and research-peptide landscape.

## Evidence maturity

GHK-Cu is, by a wide margin, the most mature of the three: decades of cell and animal work, a real body of small human topical trials, and one placebo-controlled human hair-growth trial with a statistically significant result [3]. GLOW inherits none of that maturity as a combination — every specific claim on its page traces to a single-ingredient study, and the 2026 review that names all three ingredients together is explicit that rigorous human safety data for compounds like these remain scarce [8]. Melanotan II's efficacy evidence is real but small in scale — a 10-person crossover trial for its erectile effect [15] — while its safety literature is unusually extensive for a compound this size, almost entirely because of published case reports documenting serious harm.

## Safety profile

This is where the three separate most sharply. GHK-Cu's safety concerns are mostly about topical irritation and formulation compatibility, with theoretical (not documented) concerns about systemic copper accumulation if it were used by injection. GLOW inherits GHK-Cu's copper caution plus two additional and more serious ones: its TB-500 ingredient is WADA-prohibited for tested athletes, and its BPC-157 ingredient's pro-angiogenic mechanism raises a theoretical caution for anyone with an active or recent cancer. Melanotan II carries the heaviest documented burden of the three — published case reports of new and changing moles, melanoma, rhabdomyolysis, kidney infarction, priapism, and a brain-swelling condition (PRES), on top of a market where analytical testing repeatedly finds mislabeled or inconsistent product. None of the three is approved for any anti-aging or cosmetic indication in the way this site discusses them, and none should be read as recommended for human use here.

---

A plainspoken literature desk on skin, pigment, and repair peptide research — citations and context, never a clinic, a vendor, or a prescription.